{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-017067","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.407219+00:00","generated_at":"2026-05-26T05:17:28.877457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmuCell Q4 product sales up 52% to $7.8M; net income $515k vs loss year ago","bullets":["Product sales for Q4 2024 rose 52% to ~$7.8M; full-year sales up 52% to ~$26.5M.","Q4 net income of $515k ($0.06 diluted EPS) vs net loss of $1.14M ($0.15) in Q4 2023.","Gross margin improved to 37% in Q4 2024 from 25% in Q4 2023; EBITDA turned positive at $1.33M.","No contamination events since April 2024; management believes remediation is effective.","Pending FDA clearance for Re-Tain®; NADA submitted Jan 2025 seeking expedited review."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-017067","json":"https://secwatch.observer/filing/0001213900-25-017067.json","markdown":"https://secwatch.observer/filing/0001213900-25-017067.md","text":"https://secwatch.observer/filing/0001213900-25-017067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390025017067/0001213900-25-017067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390025017067/ea0232079-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:17:28.877457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}